Can a 'N-of-1' trial help heart failure patients find their perfect dose?

NCT ID NCT07489352

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 4 times

Summary

This study tests a personalized approach to find the best beta-blocker dose for older adults with heart failure. Fifty participants will either receive the N-of-1 intervention (testing different doses in 2-week cycles) or enhanced usual care. The goal is to see if this patient-driven method helps achieve higher, better-tolerated doses.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: beta-blocker (metoprolol, carvedilol, or bisoprolol)
What this could lead to: If successful, this approach could help doctors and patients personalize beta-blocker dosing, improving heart failure management without side effects.
What could go wrong: This is a small, early-stage behavioral study (not testing a new drug). It may not show clear benefits, and results might not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BETA-BLOCKER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BETA-BLOCKER HEART FAILURE OLDER ADULTS

Contacts and locations

Locations

New York Presbyterian Hospital/Weill Medical College of Cornell University

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.